CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Unicycive Therapeutics, Inc. - UNCY CFD

1.71
5.56%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.62
Open* 1.58
1-Year Change* 216%
Day's Range* 1.49 - 1.73
52 wk Range 0.44-2.87
Average Volume (10 days) 276.35K
Average Volume (3 months) 3.20M
Market Cap 29.88M
P/E Ratio -100.00K
Shares Outstanding 34.75M
Revenue 675.00K
EPS -1.75
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 22, 2024 1.71 0.08 4.91% 1.63 1.79 1.49
Feb 21, 2024 1.62 0.25 18.25% 1.37 1.62 1.37
Feb 20, 2024 1.42 0.08 5.97% 1.34 1.49 1.33
Feb 16, 2024 1.34 0.07 5.51% 1.27 1.39 1.24
Feb 15, 2024 1.28 0.13 11.30% 1.15 1.29 1.14
Feb 14, 2024 1.14 0.07 6.54% 1.07 1.14 1.05
Feb 13, 2024 1.03 0.03 3.00% 1.00 1.03 0.97
Feb 12, 2024 1.03 0.00 0.00% 1.03 1.07 0.98
Feb 9, 2024 1.08 -0.05 -4.42% 1.13 1.15 1.08
Feb 8, 2024 1.10 -0.01 -0.90% 1.11 1.17 1.08
Feb 7, 2024 1.10 -0.02 -1.79% 1.12 1.12 1.02
Feb 6, 2024 1.07 0.09 9.18% 0.98 1.16 0.98
Feb 5, 2024 0.97 0.05 5.43% 0.92 1.01 0.89
Feb 2, 2024 0.91 -0.03 -3.19% 0.94 0.94 0.90
Feb 1, 2024 0.91 -0.02 -2.15% 0.93 0.94 0.89
Jan 31, 2024 0.91 0.01 1.11% 0.90 0.92 0.90
Jan 30, 2024 0.91 0.01 1.11% 0.90 0.92 0.87
Jan 29, 2024 0.91 0.02 2.25% 0.89 0.91 0.85
Jan 26, 2024 0.86 -0.04 -4.44% 0.90 0.91 0.84
Jan 25, 2024 0.91 -0.01 -1.09% 0.92 0.93 0.91

Unicycive Therapeutics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.951 0 0 0 0
Total Operating Expense 19.003 8.958 2.02 1.963 0.952
Selling/General/Admin. Expenses, Total 6.567 2.897 1.005 1.168 0.608
Research & Development 12.436 6.08 1.015 0.795 0.344
Operating Income -18.052 -8.958 -2.02 -1.963 -0.952
Interest Income (Expense), Net Non-Operating -0.006 -0.628 -0.244 -0.139 -0.168
Other, Net 0 -0.431 0 -0.063 0
Net Income Before Taxes -18.058 -10.017 -2.264 -2.165 -1.12
Net Income After Taxes -18.058 -10.017 -2.264 -2.165 -1.12
Net Income Before Extra. Items -18.058 -10.017 -2.264 -2.165 -1.12
Net Income -18.058 -10.017 -2.264 -2.165 -1.12
Income Available to Common Excl. Extra. Items -18.058 -10.017 -2.264 -2.165 -1.12
Income Available to Common Incl. Extra. Items -18.058 -10.017 -2.264 -2.165 -1.12
Diluted Net Income -18.058 -10.017 -2.264 -2.165 -1.12
Diluted Weighted Average Shares 15.057 14.9965 14.4969 14.4969 14.4969
Diluted EPS Excluding Extraordinary Items -1.19931 -0.66795 -0.15617 -0.14934 -0.07726
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -1.19931 -0.66922 -0.15617 -0.14934 -0.07726
Unusual Expense (Income) 0 -0.019 0 0
Revenue 0.951
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0.675 0 0.951 0
Total Operating Expense 4.322 4.877 5.325 6.505 3.636
Selling/General/Admin. Expenses, Total 2.055 1.847 1.485 1.702 1.776
Research & Development 2.267 3.03 3.84 4.803 1.86
Unusual Expense (Income) 0 0 0
Operating Income -4.322 -4.202 -5.325 -5.554 -3.636
Interest Income (Expense), Net Non-Operating 0.202 0.002 -0.003 -0.003 0
Other, Net 0.282 -10.375 0 0
Net Income Before Taxes -3.838 -14.575 -5.328 -5.557 -3.636
Net Income After Taxes -3.838 -14.575 -5.328 -5.557 -3.636
Net Income Before Extra. Items -3.838 -14.575 -5.328 -5.557 -3.636
Net Income -3.838 -14.575 -5.328 -5.557 -3.636
Income Available to Common Excl. Extra. Items -4.441 -14.767 -5.328 -5.557 -3.636
Income Available to Common Incl. Extra. Items -4.441 -14.767 -5.328 -5.557 -3.636
Diluted Net Income -4.441 -14.767 -5.328 -5.557 -3.636
Diluted Weighted Average Shares 15.2346 15.2324 15.077 15.062 15.0287
Diluted EPS Excluding Extraordinary Items -0.29151 -0.96945 -0.35339 -0.36894 -0.24194
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.29151 -0.96945 -0.35339 -0.36894 -0.24194
Revenue 0 0.675 0 0.951
Total Adjustments to Net Income -0.603 -0.192
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2.644 18.411 0.204 0.019 0.029
Cash and Short Term Investments 0.455 16.579 0 0.015 0.025
Cash 0.455 16.579 0 0.015 0.025
Prepaid Expenses 2.189 1.832 0.004 0.004 0.004
Other Current Assets, Total 0.2 0 0
Total Assets 2.818 18.744 0.204 0.019 0.029
Total Current Liabilities 3.284 2.105 2.875 0.903 1.235
Accounts Payable 0.892 0.742 0.184 0.322 0.06
Accrued Expenses 2.392 1.363 0.168 0.013 0.017
Notes Payable/Short Term Debt 0 0 0.986 0.46 0.147
Current Port. of LT Debt/Capital Leases 0 1.528 0 0.9
Other Current Liabilities, Total 0 0.009 0.108 0.111
Total Liabilities 3.284 2.26 2.875 0.903 1.235
Total Long Term Debt 0 0 0 0 0
Total Equity -0.466 16.484 -2.671 -0.884 -1.206
Common Stock 0.015 0.015 0.037 0.036 0.034
Additional Paid-In Capital 33.516 32.408 3.214 2.738 0.253
Retained Earnings (Accumulated Deficit) -33.997 -15.939 -5.922 -3.658 -1.493
Total Liabilities & Shareholders’ Equity 2.818 18.744 0.204 0.019 0.029
Total Common Shares Outstanding 15.2317 14.9965 14.4969 14.4969 14.4969
Property/Plant/Equipment, Total - Net 0.174 0.333
Property/Plant/Equipment, Total - Gross 0.181 0.334
Accumulated Depreciation, Total -0.007 -0.001
Other Liabilities, Total 0 0.155
Preferred Stock - Non Redeemable, Net 0 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 18.569 21.93 26.184 2.644 9.962
Cash and Short Term Investments 14.345 18.818 24.332 0.455 7.01
Cash 14.345 18.818 24.332 0.455 7.01
Prepaid Expenses 4.224 3.112 1.852 2.189 2.952
Other Current Assets, Total
Total Assets 19.442 22.883 27.202 2.818 10.177
Total Current Liabilities 15.456 15.419 15.97 3.284 5.522
Accounts Payable 1.084 0.503 0.79 0.892 2.292
Accrued Expenses 2.844 1.992 1.974 2.392 3.23
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 11.528 12.924 13.206
Total Liabilities 16.008 16.053 16.685 3.284 5.551
Total Long Term Debt 0 0 0 0 0
Total Equity 3.434 6.83 10.517 -0.466 4.626
Common Stock 0.035 0.015 0.015 0.015 0.015
Additional Paid-In Capital 60.098 33.023 33.475 33.516 33.28
Retained Earnings (Accumulated Deficit) -56.743 -52.41 -48.572 -33.997 -28.669
Total Liabilities & Shareholders’ Equity 19.442 22.883 27.202 2.818 10.177
Total Common Shares Outstanding 34.7544 15.236 15.2338 15.2317 15.0879
Property/Plant/Equipment, Total - Net 0.873 0.953 1.018 0.174 0.215
Other Liabilities, Total 0.552 0.634 0.715 0 0.029
Preferred Stock - Non Redeemable, Net 0.044 25.599 0 0
Property/Plant/Equipment, Total - Gross 0.887 0.965 1.026 0.181 0.221
Accumulated Depreciation, Total -0.014 -0.012 -0.008 -0.007 -0.006
Redeemable Preferred Stock 26.202
Total Preferred Shares Outstanding 0.04365 0.03019
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -18.058 -10.017 -2.264 -2.165 -1.12
Cash From Operating Activities -15.651 -5.767 -1.459 -1.176 -0.775
Non-Cash Items 1.222 4.354 0.971 0.684 0.339
Cash Taxes Paid 0 0 0.001 0.002 0
Changes in Working Capital 1.178 -0.105 -0.166 0.305 0.006
Cash From Financing Activities -0.471 22.375 1.444 1.166 0.8
Financing Cash Flow Items -0.482 0 -0.117 0 0
Issuance (Retirement) of Stock, Net 0.011 22.39 0.141 1.166 0.25
Issuance (Retirement) of Debt, Net 0 -0.015 1.42 0 0.55
Net Change in Cash -16.124 16.579 -0.015 -0.01 0.025
Cash From Operating Activities 0.007 0.001
Cash From Investing Activities -0.002 -0.029
Capital Expenditures -0.002 -0.029
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -14.575 -18.058 -12.73 -7.173 -3.537
Cash From Operating Activities -3.92 -15.651 -9.567 -6.004 -2.957
Non-Cash Items 10.562 1.222 0.964 0.659 0.327
Cash Taxes Paid 0 0 0 0
Changes in Working Capital 0.091 1.178 2.194 0.506 0.251
Cash From Financing Activities 27.797 -0.471 0 0 0
Financing Cash Flow Items -0.24 -0.482 0
Issuance (Retirement) of Stock, Net 28.037 0.011 0 0 0
Issuance (Retirement) of Debt, Net 0 0 0 0
Net Change in Cash 23.877 -16.124 -9.569 -6.006 -2.959
Cash From Operating Activities 0.002 0.007 0.005 0.004 0.002
Cash From Investing Activities 0 -0.002 -0.002 -0.002 -0.002
Capital Expenditures 0 -0.002 -0.002 -0.002 -0.002
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Gupta (Shalabh K) Individual Investor 17.1887 5973461 104612 2023-07-11 LOW
Vivo Capital, LLC Venture Capital 9.9854 3470152 3470152 2023-07-11 LOW
Armistice Capital LLC Hedge Fund 2.8085 976000 176000 2022-12-31 MED
Rosalind Advisors, Inc. Hedge Fund 2.7897 969484 0 2023-04-27 LOW
Nantahala Capital Management, LLC Hedge Fund 1.8629 647416 0 2023-06-30 MED
Jermasek (Douglas) Individual Investor 0.5036 175012 104612 2023-07-11 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.3311 115057 0 2023-06-30 LOW
Laumas (Sandeep) Individual Investor 0.3045 105815 0 2023-04-27
Goldman Sachs & Company, Inc. Research Firm 0.276 95931 95931 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.1921 66752 -29146 2023-06-30 LOW
Ryan (John L) Individual Investor 0.1673 58140 0 2023-04-27
Gupta (Pramod) Individual Investor 0.1204 41845 41845 2023-07-11
Schiller (Brigitte) Individual Investor 0.1201 41738 0 2023-04-27 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.1008 35036 0 2023-06-30 LOW
Ground Swell Capital, LLC Investment Advisor 0.0576 20001 20001 2023-06-30 HIGH
Frontier Wealth Management LLC Investment Advisor 0.0541 18800 0 2022-06-30 LOW
CAPTRUST Financial Advisors Investment Advisor 0.0541 18800 0 2023-06-30 LOW
Tandem Capital Management, Inc. Investment Advisor 0.0446 15500 0 2023-09-30 LOW
Two Sigma Investments, LP Hedge Fund 0.0437 15200 600 2023-06-30 HIGH
Centiva Capital, LP Hedge Fund 0.0437 15186 15186 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Unicycive Therapeutics, Inc. Company profile

About Unicycive Therapeutics Inc

Unicycive Therapeutics, Inc. is a biotechnology company dedicated to developing treatments for certain medical conditions. The Company is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Unicycive Therapeutics Inc revenues was not reported. Net loss increased from $1.4M to $7.3M. Higher net loss reflects Research and development - Balancing v increase from $516K to $4.2M (expense), General and administrative - Balancing increase from $626K to $1.5M (expense), Interest expense increase from $81K to $628K (expense).

Industry: Biotechnology & Medical Research (NEC)

4300 El Camino Real, Suite 210
LOS ALTOS
CALIFORNIA 94022
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.54 Price
-2.440% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

77.78 Price
-0.640% 1D Chg, %
Long position overnight fee 0.0162%
Short position overnight fee -0.0381%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

17,973.60 Price
+0.050% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

50,916.50 Price
-1.490% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading